|
Jul 31
|
IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen
|
|
Jul 29
|
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event
|
|
Jul 23
|
How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%
|
|
Jun 25
|
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer
|
|
Jun 24
|
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
|
|
Jun 18
|
Investors in IDEAYA Biosciences (NASDAQ:IDYA) have seen impressive returns of 277% over the past five years
|
|
May 8
|
IDEAYA Biosciences First Quarter 2024 Earnings: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)
|
|
May 7
|
IDEAYA Biosciences Inc (IDYA) Reports Q1 2024 Earnings: Financial and Strategic Developments
|
|
May 7
|
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 1
|
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
|
|
Apr 24
|
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
|
|
Apr 22
|
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
|
|
Apr 1
|
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
|
|
Mar 27
|
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
|
|
Mar 12
|
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
|
|
Mar 4
|
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
|
|
Feb 23
|
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Analysts Are Pretty Bullish On The Stock After Recent Results
|
|
Jan 15
|
IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last?
|
|
Dec 5
|
IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event
|
|
Dec 4
|
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer
|